U.S. and EU Patent Office decisions invalidate Amgen subsidiary Immunex's patents
Regeneron announced the EPO revoked Immunex's European Patent No. 2,990,420 in its entirety because the claims were invalid for insufficiency of disclosure. This follows a decision the USPTO to invalidate all 17 claims of Immunex's U.S. Patent No. 8,679,487 as obvious. February 15, 2019